BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com
Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease (SATBRAD) - protocol for a prospective historically controlled study

| Journal:          | BMJ Open                      |
|-------------------|-------------------------------|
| Manuscript ID     | bmjopen-2021-054381           |
| Article Type:     | Protocol                      |
| Date Submitted by the Author: | 12-Jun-2021                  |
| Complete List of Authors: | Huang, Yen-Chu; Chiayi Chang Gung Memorial Hospital, Neurology Lee, Jiann-Der; Chang Gung Memorial Hospital Chiayi Branch, Neurology Weng, Hsu-Huei; Chang Gung Memorial Hospital Chiayi Branch, Diagnostic Radiology Lin, Leng-Chieh; Chang Gung Memorial Hospital Chiayi Branch, Department of Emergency Medicine Tsai, Yuan-Hsiung; Chang Gung Memorial Hospital Chiayi Branch, Radiology; Yang, Jen-Tsung; Chang Gung Memorial Hospital Chiayi Branch, Neurosurgery |
| Keywords:         | STROKE MEDICINE, VASCULAR MEDICINE, Magnetic resonance imaging < RADIOTHERAPY, Neuroradiology < NEUROLOGY, Stroke < NEUROLOGY |

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease (SATBRAD) - protocol for a prospective historically controlled study

Yen-Chu Huang¹, MD; Jiann-Der Lee¹, MD; Hsu-Huei Weng², MD, MPH, PhD; Leng-Chieh Lin⁴, MD; Yuan-Hsiung Tsai², MD, PhD; Jen-Tsung Yang³*, MD, PhD.

¹Department of Neurology, ²Department of Diagnostic Radiology, ³Department of Neurosurgery and Department of Emergency Medicine⁴, Chang Gung Memorial Hospital at Chiayi, Chang-Gung University College of Medicine, Taiwan

Word count: 3895

* Corresponding author: Jen-Tsung Yang

Department of Neurology, Chang Gung Memorial Hospital

No. 6 West Chia-Pu Road, Putz City, Chiayi County, Taiwan

E-mail: jents716@ms32.hinet.net

Phone: +886 5 3621000 ext. 2759    Fax: +886 5 3623002
Abstract

Introduction:

Branch atheromatous disease (BAD) contributes to small-vessel occlusion in cases of occlusion or stenosis of large caliber penetrating arteries, and it is associated with a higher possibility of early neurological deterioration (END) and recurrent stroke in acute ischemic stroke. As the pathology of BAD is due to atherosclerosis, we postulate that early intensive medical treatment with dual antiplatelet therapy (DAPT) and high-intensity statins, may prevent END and recurrent stroke in acute small subcortical infarction caused by BAD.

Methods and analysis:

In this prospective, single-group cohort study, we will compare early DAPT and high-intensity statin treatment with a historical control group of BAD patients who were treated with single antiplatelet therapy without high-intensity statin treatment. Patients will be eligible for enrollment if they are admitted for acute ischemic stroke within 24h, have a National Institutes of Health Stroke Scale (NIHSS) score of 1-8 and are diagnosed with BAD by MRI. Patients will take aspirin, clopidogrel and high-intensity statins (atorvastatin or rosuvastatin) within 24h of stroke onset, followed by aspirin or clopidogrel alone from day 22. The primary endpoint is the percentage of patients who develop END within 7 days of stroke onset (defined as an increase in the NIHSS score ≥2 points) and recurrent stroke within 30 days. The total sample sizes will be 138 for the intervention group and 277 for the control group. A historical control group will be drawn from previous prospective observation studies.

Ethics and dissemination:

The protocol of this study has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (202001386A3). All participants will have to sign and date an informed consent form. The findings arising from this study will be disseminated in peer-reviewed journals and academic conferences.
Trial registration number: ClinicalTrials.gov Identifier: NCT04824911

Keywords: Statin, antiplatelet therapy, early neurological deterioration, recurrent stroke, branch atheromatous disease

Strengths and limitations of this study

1. This will be the first trial to evaluate the effectiveness of dual antiplatelet therapy and high-intensity statins for the prevention of early neurological deterioration and recurrent stroke in patients with acute ischemic stroke from branch atheromatous disease.

2. The findings will provide valuable information to increase understanding of the effectiveness of early intensive medical treatment for branch atheromatous disease after acute stage.

3. A randomized controlled study with a parallel control arm receiving single antiplatelet treatment for milder stroke is against the latest guidelines so it’s inevitable to conduct this trial with a historical control group.

4. The use of a historical control group has the inherent drawbacks of nonrandomization and nonblinding so we cannot exclude the possibility of selection, performance, detection and attrition bias.
1. Introduction

Small-vessel occlusion is the most common stroke subtype in Asians; it is caused by the occlusion of deep perforating arteries, mainly by the underlying pathologies of lipohyalinosis or cerebral amyloid angiopathy.\textsuperscript{1,2} Branch atheromatous disease (BAD) has also been reported to contribute to small-vessel occlusion in cases of occlusion or stenosis that occur at the origin of large caliber penetrating arteries, due to microatheromas or junctional atherosclerotic plaques.\textsuperscript{3} BAD is associated with an increased possibility of early neurological deterioration (END) and recurrent stroke, especially progressive motor deficits, compared with infarction due to hypertensive arteriopathy.\textsuperscript{4-6} It has been proposed that BAD should be classified as large artery atherosclerosis rather than small vessel occlusion.\textsuperscript{7}

Following acute ischemic stroke, single antiplatelet agents, such as aspirin or clopidogrel, are the mainstay treatment for recurrent stroke prevention. However, the modest effects of single antiplatelet therapy led to the study of combination antiplatelet therapy for the prevention of recurrent stroke. The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials showed that dual antiplatelet therapy (DAPT) might be beneficial for reducing the probability of ischemic events in patients with high-risk transient ischemic attack (TIA) or minor stroke.\textsuperscript{8,9} However, these studies included all non-embolic ischemic stroke types. Some studies also showed that DAPT reduced the possibility of END.\textsuperscript{10,11} A retrospective observation study showed that DAPT was beneficial for the primary outcomes of stroke recurrence, myocardial infarction, and all-cause death in patients with large atherosclerotic stroke.\textsuperscript{12}

For patients with acute ischemic stroke, the guidelines suggest starting or continuing statin treatment as soon as oral medications can be used safely.\textsuperscript{13} Current guidelines also recommend high- or moderate-intensity statin therapy, independent of the baseline low-density lipoprotein cholesterol (LDL-C), to reduce the risk of stroke and cardiovascular events for patients with TIA or ischemic stroke of atherosclerotic origin.\textsuperscript{14} High-dose statin treatment in the acute phase of ischemic stroke and TIA significantly reduced National Institutes of Health Stroke Scale (NIHSS) scores and improved
short-term functional outcomes without increasing related adverse events; it also effectively stabilized symptomatic intracranial atherosclerotic plaques as documented by high-resolution MRI.

DAPT and high-intensity statins are the mainstay treatments for intracranial atherosclerosis (ICAS). As BAD and ICAS share the same pathology as atherosclerosis, we postulate that early intensive medical treatment with DAPT and high-intensity statins may prevent early neurological deterioration and recurrent stroke. This study aims to evaluate whether intensive medical therapy with aspirin, clopidogrel and high-intensity statins, can prevent END and recurrent stroke in acute small subcortical infarction caused by BAD.

2. Methods

2.1 Study Design

In this prospective, non-randomized, historically controlled study, we will compare early intensive treatment for BAD initiated within 24h of stroke onset, using dual antiplatelet therapy (aspirin plus clopidogrel) and high-intensity statin treatment, with a historical control group of BAD patients treated with single antiplatelet therapy, without high-intensity statin treatment. The study will be conducted in Chang Gung Memorial Hospital at Chiayi, Taiwan from March 2021 to Feb 2023.

2.2 Study population

Patients are eligible to participate if they meet the following inclusion criteria: (1) have a clinical diagnosis of ischemic stroke with an NIHSS score of 1-8 (2) have an ischemic lesion on diffuse-weighted imaging located in the striatocapsular territory or brain stem areas, with an axial diameter ≤20mm (3) have BAD, defined by a visible lesion in three or more axial MRI cuts in the lenticulostriate territory or infarcts that extend from the basal surface of the pons (4) could receive intensive medical treatment within 24h of stroke onset. Patients with >50% stenosis of the relevant arteries on magnetic resonance angiography (MRA), including intra- or extra-cranial internal carotid artery, middle cerebral artery or basilar artery, will be excluded. We will also
exclude patients at high risk of cardioembolic stroke, such as those with atrial fibrillation or heart failure. Full details of the inclusion and exclusion criteria are listed in Table 1.

A historical control group will be drawn from our prospective observation studies, which have been executed between January 2011 and December 2020, and aimed to evaluate and predict END or atrial fibrillation.\textsuperscript{18, 19} Patients will be selected if they fulfill the following inclusion criteria: took aspirin or clopidogrel alone and did not receive high-intensity statin treatment. Patients in the historical control group will have received statin treatment once their total cholesterol was \( \geq 160 \text{mg/dl} \) or their LDL-C was \( \geq 100 \text{mg/dl} \). High-intensity statin treatment includes atorvastatin 40–80mg or rosuvastatin 20–40mg daily.\textsuperscript{20} All clinical information and outcomes have been prospectively recorded.

\subsection*{2.3 Trial intervention}

Dual antiplatelet and high-intensity statin treatment will be administered within 24h of stroke onset (Figure 1). Dual antiplatelet treatment includes aspirin (300mg loading and 100mg/day) and clopidogrel (300mg loading and 75mg/day) and high-intensity statins includes atorvastatin 40–80mg/day or rosuvastatin 20mg/day. Patients will take aspirin and clopidogrel for 21 days and then just take aspirin or clopidogrel alone. High-intensity statins will be maintained for 90 days but a decreased dose is allowed if any side effects occur, including elevated liver functions, elevated creatine-phospho-kinase (CPK) and myalgia or at the judgment of the treating physician. We will follow up with alanine aminotransferase (ALT) and CPK 14 days after treatment and will follow up with ALT, CPK and LDL-C 90 days after treatment. Patients with atherosclerotic plaques in the first MRI will keep high-intensity statin treatment for 6 months.

Neurological deficits will be evaluated by a stroke study nurse using the NIHSS, at the 1\textsuperscript{st}, 2\textsuperscript{nd}, 3\textsuperscript{rd}, 7\textsuperscript{th} and 90\textsuperscript{th} day. As END in lacunar infarction is mainly associated with motor deficits, END is defined as an NIHSS score increase \( \geq 2 \) within 7 days of stroke onset.\textsuperscript{21} Clinical outcomes at admission and at 90 days will be evaluated using the modified Rankin Scale (mRS). A good outcome is defined as an mRS score \( \leq 1 \). Mortality at 3 months and any hemorrhagic complications
will also be recorded. All examinations will be performed after obtaining written informed consent from the patients or the appropriate family members.

Patients with visible atheromatous plaques in the parental artery in the initial MRI will receive a follow-up MRI 6 months later to see the interval changes in atheromatous plaques.

2.4 Study Outcomes

The primary outcome will be the percentage of patients with early neurological deterioration within 7 days and recurrent ischemic stroke within 30 days. Secondary outcomes will include: (1) the percentage of patients with favorable functional recovery, defined as an mRS \(\leq 1\) at the 90th day, (2) the percentage of patients with new clinical vascular events within 90 days, including ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular death, (3) changes in atherosclerotic plaques, which will be measured by high-resolution MRI at the start of the study and after 6 months, (4) the number of moderate to severe bleeding events as defined by the GUSTO classification, and (5) the total mortality rate.

2.5 Sample Size

In single subcortical infarction, END was reported to occur frequently in BAD with an incidence of 27% in our previous cohort and 33.8-40% in other studies. The END rate may decrease to 9.7% in patients with BAD who underwent combination antiplatelet therapy with cilostazol. The total sample sizes will be 138 for the intervention group and 277 for the control group. The estimated END rate is 27% for the control group and 15% for the intervention group, with 80% power and a two-sided alpha of 0.05. The intent-to-treat (ITT) principle will be applied to the primary outcome analysis, and the sample size was therefore inflated to safeguard against 5% lost-to-follow-up in the actual treatment groups, which could dilute the effect size.

2.6 Statistical analysis

Statistical analyses will be performed using the Statistical Package for the Social Sciences (SPSS) statistical software (version 25, Chicago, IL, USA). The Kolmogorov-Smirnov test will be used to examine the normality of continuous variables. The Mann-Whitney U test and
Student’s t-test will be used to test for differences between the two groups, as appropriate. Categorical data will be analyzed using the Chi-squared test. A logistic regression model will be used to adjust for baseline confounding factors and to test independent variables for the measured outcomes. Variables showing a p value of <0.1 for univariate analysis will be entered into the multivariate logistic analysis using the forward selection method. All tests will be two-tailed, and a p value <0.05 is considered to indicate a statistically significant difference.

2.7 Data management

All the completed documents and the informed consent forms will be stored in a secured facility, under lock and key. The database for clinical data will be created using Access software and the access will be limited to principal investigators. A study steering committee will be established to ensure that the study conducted to the required standards. The clinical research assistant will verify all consent forms, compliance with study protocol and procedures, and data quality. The research team will make half-yearly reports to the study steering committee. All the records and documents will be kept for 7 years after the completion of the study.

2.8 Adverse events

Any adverse events that occur during the conduct of the study will be reported to the Domain Specific Research Board (DSRB) according to the local institutional policy. Interim analyses will be conducted by the study steering committee to monitor the accumulating data and to decide continuing or stopping the trial.

2.9 Patient and public involvement:

Patients and members from stroke associations participated in the preparation and formulation of this proposal. Patients with acute ischemic stroke from BAD will be involved in the trial. The associations will be involved in plans to disseminate the study results to their members and wider patient communities.

2.10 Ethics and dissemination:

The protocol of this study has been approved by the Institutional Review Board of Chang Gung
Memorial Hospital (202001386A3). The study is registered on ClinicalTrials.gov (NCT04824911). All participants will have to sign and date an informed consent form. The findings arising from this study will be disseminated in peer-reviewed journals and academic conferences. The datasets during the current study are available from the corresponding author on reasonable request.

3. Discussion

This will be the first trial to evaluate the effectiveness of DAPT and high-intensity statins for the prevention of early neurological deterioration and recurrent stroke in patients with acute ischemic stroke from BAD. With improvements in imaging, BAD is believed to be caused by atherosclerotic plaques which obstruct the orifices of penetrators and it has been proposed that BAD should be classified as large artery atherosclerosis rather than small vessel occlusion. DAPT and high-intensity statins are the mainstay treatments for ICAS. Since ICAS and BAD share the same pathology of atherosclerosis, the treatment of DAPT and high-intensity statins may also be effective for BAD. The results of this trial will answer the question of whether optimal treatment for BAD is different from other small subcortical infarction due to other pathologies.

In this trial, we define BAD as a visible lesion in three or more axial MRI cuts in the lenticulostriate territory or infarcts that extend from the basal surface of the pons. Although high-resolution vessel-wall MRIs provide a direct way of detecting atherosclerotic plaques involving perforators’ parent arteries, the definition in this trial is a more practical way of stroke diagnosis. In addition, microatheroma in the proximal penetrating artery are not visible in vessel-wall imaging and need other advanced sequences to be detected, which may prohibit its widespread use.

Our primary outcome is the percentage of patients with END within 7 days and recurrent ischemic stroke within 30 days, which often lead to greater mortality and functional disability. It is therefore worth evaluating any treatment which could lower END and recurrent stroke. In the secondary outcomes, we will evaluate the changes in atherosclerotic plaques on parental arteries as measured by an initial high-resolution MRI and another 6 months later. To the best of our knowledge, it will be the
first trial to demonstrate plaque changes in BAD after medical treatment.

There are several methodological limitations of this trial. The use of a historical control group has the inherent drawbacks of nonrandomization and nonblinding so we cannot exclude the possibility of selection, performance, detection and attrition bias. However, using a single antiplatelet agent for milder stroke with an NIHSS score $\leq 3$ is against the guidelines and there would be ethical issues if we conducted a randomized controlled study with a parallel control arm receiving single antiplatelet treatment. Therefore, our study still provides valuable information to increase understanding of the effectiveness of DAPT and statins in acute small subcortical infarction from BAD.

Author contributions

YCH and JTY conceptualized and designed the initial protocol. JDL, LCL, HHW and YHT amended the initial protocol. YCH drafted the manuscript and received the fund. All authors read and approved of the protocol prior to submission.

Funding

This work was supported by Chang Gung Memorial Hospital research grants (CORPG6K0161).

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.
References

1. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. *Int J Stroke* 2016;11:6-18.

2. Kim BJ, Kim JS. Ischemic stroke subtype classification: an asian viewpoint. *J Stroke* 2014;16:8-17.

3. Petrone L, Nannoni S, Del Bene A, et al. Branch Atheromatous Disease: A Clinically Meaningful, Yet Unproven Concept. *Cerebrovasc Dis* 2016;41:87-95.

4. Yamamoto Y, Ohara T, Hamanaka M, et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. *J Neurol Sci* 2011;304:78-82.

5. Kim JS, Yoon Y. Single subcortical infarction associated with parental arterial disease: important yet neglected sub-type of atherothrombotic stroke. *Int J Stroke* 2013;8:197-203.

6. Ko Y, Lee S, Chung JW, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. *J Stroke* 2014;16:161-72.

7. Gao S, Wang YJ, Xu AD, et al. Chinese ischemic stroke subclassification. *Front Neurol* 2011;2:6.

8. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. *N Engl J Med* 2018;379:215-25.

9. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013;369:11-9.

10. Kimura T, Tucker A, Sugimura T, et al. Ultra-Early Combination Antiplatelet Therapy with Cilostazol for the Prevention of Branch Atheromatous Disease: A Multicenter Prospective Study. *Cerebrovasc Dis Extra* 2016;6:84-95.

11. Wang C, Yi X, Zhang B, et al. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. *Clin Appl Thromb Hemost* 2015;21:453-61.

12. Kim D, Park JM, Kang K, et al. Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. *Stroke* 2019;50:1184-92.

13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e1082-e143.

14. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:S1-45.

15. Fang JX, Wang EQ, Wang W, et al. The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review. *Intern Emerg Med* 2017;12:679-87.

16. Chung JW, Cha J, Lee MJ, et al. Intensive Statin Treatment in Acute Ischaemic Stroke Patients
with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study). *J Neurol Neurosurg Psychiatry* 2020;91:204-11.

17. Liu D, Liu J, Cai Y, et al. Is the future of symptomatic intracranial atherosclerotic stenosis management promising? *J Neurol Neurosurg Psychiatry* 2020;91:122-24.

18. Huang WY, Lee M, Sung SF, et al. Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial. *Int J Stroke* 2021;16:300-10.

19. Huang YC, Tsai YH, Lee JD, et al. A Novel Neuroimaging Model to Predict Early Neurological Deterioration After Acute Ischemic Stroke. *Curr Neurovasc Res* 2018;15:129-37.

20. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016;388:2532-61.

21. Siegler JE, Martin-Schild S. Early Neurological Deterioration (END) after stroke: the END depends on the definition. *Int J Stroke* 2011;6:211-2.

22. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736-47.

23. van Rooij WJ, Sprengers ME, de Gast AN, et al. 3D rotational angiography: the new gold standard in the detection of additional intracranial aneurysms. *AJNR Am J Neuroradiol* 2008;29:976-9.

24. Jiang S, Wu S, Zhang S, et al. Advances in Understanding the Pathogenesis of Lacunar Stroke: From Pathology and Pathophysiology to Neuroimaging. *Cerebrovasc Dis* 2021:1-9.
**Figure 1.** A schematic diagram of the treatment schedule and study design.

In the intervention group, patients will take aspirin (300mg loading and 100mg/day), clopidogrel (300mg loading and 75mg/day) and high-intensity statins (atorvastatin 40-80mg/day or rosuvastatin 20mg/day) within 24h of stroke onset, followed by aspirin or clopidogrel alone from day 22. High-intensity statins includes atorvastatin 40-80mg/day or rosuvastatin 20mg/day. In the historical control group, patients will be selected from previous prospective studies if they fulfill the following inclusion criteria: took aspirin or clopidogrel alone and did not receive high-intensity statin treatment.
Table 1. Inclusion and exclusion criteria (Issue date: 01 Sep 2020)

### Inclusion Criteria

- Clinical diagnosis of ischemic stroke with a National Institute of Health Stroke Scale (NIHSS) score of 1-8
- An ischemic lesion on diffuse-weighted imaging located in the striatocapsular territory or brain stem areas, with an axial diameter ≤20mm.
- Branch atheromatous disease, defined by a visible lesion in three or more axial MRI cuts in the lenticulostriate territory or infarcts that extend from the basal surface of the pons
- Ability to participate within 24h of the time of last known free of new ischemic symptoms.
- Head MRI ruling out hemorrhage or other pathologies, such as vascular malformation, tumor, or abscess, that could explain their symptoms or contraindicate therapy.
- Ability to tolerate high intensity medical therapy, including aspirin at a dose of 50–325mg/day, clopidogrel at 300mg loading and 75mg after day 2 and high-intensity statins (either atorvastatin 40-80mg or rosuvastatin 20mg/day).
- Pre-stroke mRS ≤1

### Exclusion Criteria

- Age <18 years.
- At the judgment of the treating physician
- A candidate for thrombolysis, endarterectomy or endovascular intervention.
- Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to the index event.
- Patients with >50% stenosis of the relevant arteries as determined by magnetic resonance angiography (MRA), including the intra- or extra-cranial internal carotid artery, middle cerebral artery or basilar artery.
- Patients with a high risk of cardioembolic stroke, such as those with atrial fibrillation, acute myocardial infarction, severe heart failure or valvular heart disease.
- Those with other determined stroke etiologies, such as vasculitis, shock, antiphospholipid antibody syndrome etc.
- Gastrointestinal bleeding or major surgery within 3 months prior to the index event.
- History of nontraumatic intracranial hemorrhage.
- Clear indication for anticoagulation during the study period (deep venous thrombosis, pulmonary embolism or hypercoagulable state).
- Qualifying ischemic event induced by angiography or surgery.
- Severe non-cardiovascular comorbidity with a life expectancy <3 months.
- Contraindication to clopidogrel, aspirin, atorvastatin or rosuvastatin
  - Known allergy to clopidogrel, aspirin atorvastatin or rosuvastatin
  - Severe renal (serum creatinine >2 mg/dL) or hepatic insufficiency (INR >1.2; ALT >40 U/L or any
resultant complication, such as variceal bleeding, encephalopathy, or jaundice)

- Hemostatic disorder or systemic bleeding in the past 3 months
- Current thrombocytopenia (platelet count <100 x10^9/L) or leukopenia (<2 x10^9/L)
- History of drug-induced hematologic or hepatic abnormalities
- Anticipated requirement for long-term (>7 day) non-study antiplatelet drugs (e.g., dipyridamole, ticagrelor, ticlopidine), or NSAIDs.
- Not willing or able to discontinue prohibited concomitant medications.
- Women of childbearing age not practicing reliable contraception who do not have a documented negative pregnancy test.
- Other neurological conditions that would complicate assessment of outcomes during follow-up.
- Ongoing treatment in another study of an investigational therapy, or treatment in such a study within the last 7 days.
Figure 1/ A schematic diagram of the treatment schedule and study design

199x109mm (300 x 300 DPI)
Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

**Instructions to authors**

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

| Reporting Item                                                                 | Page Number |
|-------------------------------------------------------------------------------|-------------|
| **Administrative information**                                                |             |
| Title                                                                         | #1          |
| Descriptive title identifying the study design, population, interventions, and | 1           |
| if applicable, trial acronym                                                   |             |
Trial registration  #2a  Trial identifier and registry name. If not yet registered, name of intended registry

Trial registration:  #2b  All items from the World Health Organization Trial data set Registration Data Set

Protocol version  #3  Date and version identifier

Funding  #4  Sources and types of financial, material, and other support

Roles and responsibilities:  #5a  Names, affiliations, and roles of protocol contributors

Roles and responsibilities:  #5b  Name and contact information for the trial sponsor

Roles and responsibilities:  #5c  Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities

Roles and responsibilities:  #5d  Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and
other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

**Introduction**

**Background and rationale**

- **#6a** Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention

**Background and rationale: choice of comparators**

- **#6b** Explanation for choice of comparators

**Objectives**

- **#7** Specific objectives or hypotheses

**Trial design**

- **#8** Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)

**Methods:**

**Participants, interventions, and outcomes**

**Study setting**

- **#9** Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria

Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)

Interventions:

#11a Interventions for each group with sufficient detail to allow description replication, including how and when they will be administered

#11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)

#11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)

#11d Relevant concomitant care and interventions that are permitted or prohibited during the trial

Outcomes

#12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline #13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

Sample size #14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations

Recruitment #15 Strategies for achieving adequate participant enrolment to reach target sample size

Methods:
Assignment of interventions (for controlled trials)

Allocation: sequence generation #16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

Allocation concealment mechanism #16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque,
sealed envelopes), describing any steps to conceal the sequence until interventions are assigned.

Allocation: **Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions**

Blinding (masking): **Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how**

Blinding (masking): **If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial**

**Methods: Data**

**collection, management, and analysis**

**Data collection plan** **Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol**
Data collection plan:  

#18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

Data management  

#19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistics: outcomes  

#20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

Statistics: additional analyses  

#20b Methods for any additional analyses (eg, subgroup and adjusted analyses)

Statistics: analysis population and missing data  

#20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring  

Data monitoring:  

#21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further
details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

Data monitoring:

**#21b** Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial

Harms

**#22** Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct

Auditing

**#23** Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

**Ethics and dissemination**

Research ethics

**#24** Plans for seeking research ethics committee / institutional review board (REC / IRB) approval

Protocol amendments

**#25** Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)
Consent or assent

Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)

Consent or assent: ancillary studies

Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable

Confidentiality

How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial

Declaration of interests

Financial and other competing interests for principal investigators for the overall trial and each study site

Data access

Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators

Ancillary and post-trial care

Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation

Dissemination policy: trial results

Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
Dissemination policy: **#31b** Authorship eligibility guidelines and any intended use of professional writers

Dissemination policy: **#31c** Plans, if any, for granting public access to the full reproducible protocol, participant-level dataset, and statistical code research

**Appendices**

Informed consent **#32** Model consent form and other related documentation given to participants and authorised surrogates

Biological specimens **#33** Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 08. June 2021 using [https://www.goodreports.org/](https://www.goodreports.org/), a tool made by the EQUATOR Network in collaboration with [Penelope.ai](https://www.penelope.ai)
Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease (SATBRAD) : protocol for a prospective single-arm study using a historical control for comparison

| Journal | BMJ Open |
|---------|----------|
| Manuscript ID | bmjopen-2021-054381.R1 |
| Article Type | Protocol |
| Date Submitted by the Author | 23-Oct-2021 |
| Complete List of Authors | Huang, Yen-Chu; Chang Gung Memorial Hospital Chiayi Branch, Neurology; Chang Gung University Lee, Jiann-Der; Chang Gung Memorial Hospital Chiayi Branch, Neurology; Chang Gung Memorial Hospital Chiayi Branch Weng, Hsu-Huei; Chang Gung Memorial Hospital Chiayi Branch, Diagnostic Radiology Lin, Leng-Chieh; Chang Gung Memorial Hospital Chiayi Branch, Department of Emergency Medicine Tsai, Yuan-Hsiung; Chang Gung Memorial Hospital Chiayi Branch, Radiology; Chang Gung University, Yang, Jen-Tsung; Chang Gung Memorial Hospital Chiayi Branch, Neurosurgery; Chang Gung Memorial Hospital Chiayi Branch |
| Primary Subject Heading | Neurology |
| Secondary Subject Heading | Medical management, Radiology and imaging |
| Keywords | STROKE MEDICINE, VASCULAR MEDICINE, Magnetic resonance imaging < RADIOTHERAPY, Neuroradiology < NEUROLOGY, Stroke < NEUROLOGY |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Statin and dual antiplatelet therapy for the prevention of early neurological
deterioration and recurrent stroke in branch atheromatous disease (SATBRAD):
protocol for a prospective single-arm study using a historical control for
comparison

Yen-Chu Huang¹, MD; Jiann-Der Lee¹, MD; Hsu-Huei Weng², MD, MPH, PhD; Leng-Chieh Lin⁴,
MD; Yuan-Hsiung Tsai², MD, PhD; Jen-Tsong Yang³*, MD, PhD.

¹Department of Neurology, ²Department of Diagnostic Radiology, ³Department of Neurosurgery and
Department of Emergency Medicine⁴, Chang Gung Memorial Hospital at Chiayi, Chang-Gung
University College of Medicine, Taiwan

Word count: 3537

* Corresponding author: Jen-Tsong Yang

Department of Neurology, Chang Gung Memorial Hospital

No. 6 West Chia-Pu Road, Putz City, Chiayi County, Taiwan

E-mail: jents716@ms32.hinet.net

Phone: +886 5 3621000 ext. 2759    Fax: +886 5 3623002
Abstract

Introduction:

Branch atheromatous disease (BAD) contributes to small-vessel occlusion in cases of occlusion or stenosis of large caliber penetrating arteries, and it is associated with a higher possibility of early neurological deterioration (END) and recurrent stroke in acute ischemic stroke. As the pathology of BAD is due to atherosclerosis, we postulate that early intensive medical treatment with dual antiplatelet therapy (DAPT) and high-intensity statins, may prevent END and recurrent stroke in acute small subcortical infarction caused by BAD.

Methods and analysis:

In this prospective, single-center, open-label, non-randomized, single-arm study using a historical control, we will compare early DAPT and high-intensity statin treatment with a historical control group of BAD patients who were treated with single antiplatelet therapy without high-intensity statin treatment. Patients will be eligible for enrollment if they are admitted for acute ischemic stroke within 24h, have a National Institutes of Health Stroke Scale (NIHSS) score of 1-8 and are diagnosed with BAD by MRI. Patients will take aspirin, clopidogrel and high-intensity statins (atorvastatin or rosuvastatin) within 24h of stroke onset, followed by aspirin or clopidogrel alone from day 22. The primary endpoint is the percentage of patients who develop END within 7 days of stroke onset (defined as an increase in the NIHSS score \( \geq 2 \) points) and recurrent stroke within 30 days. The total sample sizes will be 138 for the intervention group and 277 for the control group. A historical control group will be drawn from previous prospective observation studies.

Ethics and dissemination:

The protocol of this study has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (202001386A3). All participants will have to sign and date an informed consent form. The findings arising from this study will be disseminated in peer-reviewed journals and academic conferences.
Trial registration number: ClinicalTrials.gov Identifier: NCT04824911

Keywords: Statin, antiplatelet therapy, early neurological deterioration, recurrent stroke, branch atheromatous disease

Strengths and limitations of this study

1. This will be the first trial to evaluate the effectiveness of dual antiplatelet therapy and high-intensity statins for the prevention of early neurological deterioration and recurrent stroke in patients with acute ischemic stroke from branch atheromatous disease.

2. This trial will recruit patients with National Institutes of Health Stroke Scale scores of 1-8, which are more severe than current guideline suggestion of scores $\leq 3$ for mild stroke with dual antiplatelet therapy.

3. A randomized controlled study with a parallel control arm receiving single antiplatelet treatment for mild stroke is against the latest guidelines so it’s inevitable to conduct this trial with a historical control group.

4. The use of a historical control group has the inherent drawbacks of nonrandomization and nonblinding so we cannot exclude the possibility of selection, performance, detection and attrition bias.

5. Because dual antiplatelet therapy and high-intensity statin treatment are administered simultaneously, it’s unable to know each treatment effect.
1. Introduction

Small-vessel occlusion is the most common stroke subtype in Asians; it is caused by the occlusion of deep perforating arteries, mainly by the underlying pathologies of lipohyalinosis or cerebral amyloid angiopathy. Branch atheromatous disease (BAD) has also been reported to contribute to small-vessel occlusion in cases of occlusion or stenosis that occur at the origin of large caliber penetrating arteries, due to microatheromas or junctional atherosclerotic plaques. BAD is associated with an increased possibility of early neurological deterioration (END) and recurrent stroke, especially progressive motor deficits, compared with infarction due to hypertensive arteriopathy. It has been proposed that BAD should be classified as large artery atherosclerosis rather than small vessel occlusion.

Following acute ischemic stroke, single antiplatelet agents, such as aspirin or clopidogrel, are the mainstay treatment for recurrent stroke prevention. However, the modest effects of single antiplatelet therapy led to the study of combination antiplatelet therapy for the prevention of recurrent stroke. The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials showed that dual antiplatelet therapy (DAPT) might be beneficial for reducing the probability of ischemic events in patients with high-risk transient ischemic attack (TIA) or minor stroke. However, these studies included all non-embolic ischemic stroke types. Some studies also showed that DAPT reduced the possibility of END. A retrospective observation study showed that DAPT was beneficial for the primary outcomes of stroke recurrence, myocardial infarction, and all-cause death in patients with large atherosclerotic stroke.

For patients with acute ischemic stroke, the guidelines suggest starting or continuing statin treatment as soon as oral medications can be used safely. Current guidelines also recommend high- or moderate-intensity statin therapy, independent of the baseline low-density lipoprotein cholesterol (LDL-C), to reduce the risk of stroke and cardiovascular events for patients with TIA or ischemic stroke of atherosclerotic origin. High-dose statin treatment in the acute phase of ischemic stroke and TIA significantly reduced National Institutes of Health Stroke Scale (NIHSS) scores and improved
short-term functional outcomes without increasing related adverse events\textsuperscript{15}; it also effectively
stabilized symptomatic intracranial atherosclerotic plaques as documented by high-resolution MRI.\textsuperscript{16}

DAPT and high-intensity statins are the mainstay treatments for intracranial atherosclerosis (ICAS).\textsuperscript{17} As BAD and ICAS share the same pathology as atherosclerosis, we postulate that early intensive medical treatment with DAPT and high-intensity statins may prevent early neurological deterioration and recurrent stroke. This study aims to evaluate whether intensive medical therapy with aspirin, clopidogrel and high-intensity statins, can prevent END and recurrent stroke in acute small subcortical infarction caused by BAD.

2. Methods

2.1 Study Design

In this prospective, single-center, open-label, non-randomized, single-arm, historically controlled study, we will compare early intensive treatment for BAD initiated within 24h of stroke onset, using dual antiplatelet therapy (aspirin plus clopidogrel) and high-intensity statin treatment, with a historical control group of BAD patients treated with single antiplatelet therapy, without high-intensity statin treatment.\textsuperscript{18,19} The study will be conducted in Chang Gung Memorial Hospital at Chiayi, Taiwan from March 2021 to Feb 2023.

2.2 Study population

Patients are eligible to participate if they meet the following inclusion criteria: (1) have a clinical diagnosis of ischemic stroke with an NIHSS score of 1–8 (2) have an ischemic lesion on diffuse-weighted imaging (DWI) located in the striatocapsular territory or brain stem areas, with an axial diameter \( \leq 20\text{mm} \) (3) have BAD, defined by a visible ischemic lesion in three or more axial cuts on DWI in the lenticulostriate territory or infarcts that extend from the basal surface of the pons (4) could receive intensive medical treatment within 24h of stroke onset. Patients with >50% stenosis of the relevant arteries on magnetic resonance angiography (MRA), including intra- or extra-cranial internal carotid artery, middle cerebral artery or basilar artery, will be
excluded. We will also exclude patients at high risk of cardioembolic stroke, such as those with atrial fibrillation or heart failure. Full details of the inclusion and exclusion criteria are listed in Table 1.

A historical control group will be drawn from our prospective observation studies, which have been executed between January 2011 and December 2020, and aimed to evaluate and predict END or atrial fibrillation.\textsuperscript{18, 19} Patients will be selected if they fulfill the following inclusion criteria: took aspirin or clopidogrel alone and did not receive high-intensity statin treatment. Patients in the historical control group will have received statin treatment once their total cholesterol was $\geq 160\text{mg/dl}$ or their LDL-C was $\geq 100\text{mg/dl}$. High-intensity statin treatment includes atorvastatin 40–80mg or rosuvastatin 20–40mg daily.\textsuperscript{20} All clinical information and outcomes have been prospectively recorded.

\subsection*{2.3 Trial intervention}

Dual antiplatelet and high-intensity statin treatment will be administered within 24h of stroke onset (Figure 1). Dual antiplatelet treatment includes aspirin (300mg loading and 100mg/day) and clopidogrel (300mg loading and 75mg/day) and high-intensity statins includes atorvastatin 40–80mg/day or rosuvastatin 20mg/day. Patients will take aspirin and clopidogrel for 21 days and then just take aspirin or clopidogrel alone. High-intensity statins will be maintained for 90 days but a decreased dose is allowed if any side effects occur, including elevated liver functions, elevated creatine-phospho-kinase (CPK) and myalgia or at the judgment of the treating physician.

We will follow up with alanine aminotransferase (ALT) and CPK 14 days after treatment and will follow up with ALT, CPK and LDL-C 90 days after treatment. Patients with atherosclerotic plaques in the first MRI will keep high-intensity statin treatment for 6 months.

Neurological deficits will be evaluated by a stroke study nurse using the NIHSS, at the 1\textsuperscript{st}, 2\textsuperscript{nd}, 3\textsuperscript{rd}, 7\textsuperscript{th} and 90\textsuperscript{th} day. As END in lacunar infarction is mainly associated with motor deficits, END is defined as an NIHSS score increase $\geq 2$ within 7 days of stroke onset.\textsuperscript{21} Clinical outcomes at admission and at 90 days will be evaluated using the modified Rankin Scale (mRS). A good
outcome is defined as an mRS score ≤1. Mortality at 3 months and any hemorrhagic complications will also be recorded. All examinations will be performed after obtaining written informed consent from the patients or the appropriate family members.

Patients with visible atheromatous plaques in the parental artery in the initial MRI will receive a follow-up MRI 6 months later to see the interval changes in atheromatous plaques.

2.4 Study Outcomes

The primary outcome will be the percentage of patients with early neurological deterioration within 7 days and recurrent ischemic stroke within 30 days. Secondary outcomes will include: (1) the percentage of patients with favorable functional recovery, defined as an mRS ≤1 at the 90th day, (2) the percentage of patients with new clinical vascular events within 90 days, including ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular death, (3) changes in atherosclerotic plaques, which will be measured by high-resolution MRI at the start of the study and after 6 months, (4) the number of moderate to severe bleeding events as defined by the GUSTO classification,22 and (5) the total mortality rate.

2.5 Sample Size

In single subcortical infarction, END was reported to occur frequently in BAD with an incidence of 27% in our previous cohort and 33.8-40% in other studies.10 23 The END rate may decrease to 9.7% in patients with BAD who underwent combination antiplatelet therapy with cilostazol.10 The total sample sizes will be 138 for the intervention group and 277 for the control group. The estimated END rate is 27% for the control group and 15% for the intervention group, with 80% power and a two-sided alpha of 0.05. The intent-to-treat (ITT) principle will be applied to the primary outcome analysis, and the sample size was therefore inflated to safeguard against 5% lost-to-follow-up in the actual treatment groups, which could dilute the effect size.

2.6 Statistical analysis

Statistical analyses will be performed using the Statistical Package for the Social Sciences (SPSS) statistical software (version 25, Chicago, IL, USA). The Kolmogorov-Smirnov test will
be used to examine the normality of continuous variables. The Mann-Whitney U test and
Student’s t-test will be used to test for differences between the two groups, as appropriate.
Categorical data will be analyzed using the Chi-squared test. A propensity score matching
analysis will be used to measure and balance pre-determined covariates between two groups. A
logistic regression model will be used to test independent variables for the measured outcomes.
Variables showing a p value of <0.1 for univariate analysis will be entered into the multivariate
logistic analysis using the forward selection method. All tests will be two-tailed, and a p value
<0.05 is considered to indicate a statistically significant difference.

2.7 Data management

All the completed documents and the informed consent forms will be stored in a secured
facility, under lock and key. The database for clinical data will be created using Access software
and the access will be limited to principal investigators. A study steering committee will be
established to ensure that the study conducted to the required standards. The clinical research
assistant will verify all consent forms, compliance with study protocol and procedures, and data
quality. The research team will make half-yearly reports to the study steering committee. All the
records and documents will be kept for 7 years after the completion of the study.

2.8 Adverse events

Any adverse events that occur during the conduct of the study will be reported to the Domain
Specific Research Board (DSRB) according to the local institutional policy. Interim analyses will
be conducted by the study steering committee to monitor the accumulating data and to decide
continuing or stopping the trial.

2.9 Patient and public involvement:

Patients and members from stroke associations participated in the preparation and formulation of
this proposal. Patients with acute ischemic stroke from BAD will be involved in the trial. The
associations will be involved in plans to disseminate the study results to their members and wider
patient communities.
2.10 Ethics and dissemination:

The protocol of this study has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (202001386A3). The study is registered on ClinicalTrials.gov (NCT04824911). All participants will have to sign and date an informed consent form. The findings arising from this study will be disseminated in peer-reviewed journals and academic conferences. The datasets during the current study are available from the corresponding author on reasonable request.

Author contributions

YCH and JTY conceptualized and designed the initial protocol. JDL, LCL, HHW and YHT amended the initial protocol. YCH drafted the manuscript and received the fund. All authors read and approved of the protocol prior to submission.

Funding

This work was supported by Chang Gung Memorial Hospital research grants (CORPG6K0161).

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.
References

1. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. *Int J Stroke* 2016;11:6–18.

2. Kim BJ, Kim JS. Ischemic stroke subtype classification: an asian viewpoint. *J Stroke* 2014;16:8-17.

3. Petrone L, Nannoni S, Del Bene A, et al. Branch Atheromatous Disease: A Clinically Meaningful, Yet Unproven Concept. *Cerebrovasc Dis* 2016;41:87–95.

4. Yamamoto Y, Ohara T, Hamanaka M, et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. *J Neurol Sci* 2011;304:78–82.

5. Kim JS, Yoon Y. Single subcortical infarction associated with parental arterial disease: important yet neglected sub-type of atherothrombotic stroke. *Int J Stroke* 2013;8:197–203.

6. Ko Y, Lee S, Chung JW, et al. MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification. *J Stroke* 2014;16:161–72.

7. Gao S, Wang YJ, Xu AD, et al. Chinese ischemic stroke subclassification. *Front Neurol* 2011;2:6.

8. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. *N Engl J Med* 2018;379:215–25.

9. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013;369:11–9.

10. Kimura T, Tucker A, Sugimura T, et al. Ultra-Early Combination Antiplatelet Therapy with Cilostazol for the Prevention of Branch Atheromatous Disease: A Multicenter Prospective Study. *Cerebrovasc Dis Extra* 2016;6:84–95.

11. Wang C, Yi X, Zhang B, et al. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. *Clin Appl Thromb Hemost* 2015;21:453–61.

12. Kim D, Park JM, Kang K, et al. Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. *Stroke* 2019;50:1184–92.

13. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e1082–e143.

14. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:S1–45.

15. Fang JX, Wang EQ, Wang W, et al. The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review. *Intern Emerg Med* 2017;12:679–87.

16. Chung JW, Cha J, Lee MJ, et al. Intensive Statin Treatment in Acute Ischaemic Stroke Patients.
with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study). *J Neurol Neurosurg Psychiatry* 2020;91:204–11.

17. Liu D, Liu J, Cai Y, et al. Is the future of symptomatic intracranial atherosclerotic stenosis management promising? *J Neurol Neurosurg Psychiatry* 2020;91:122–24.

18. Huang WY, Lee M, Sung SF, et al. Atrial fibrillation trial to evaluate real-world procedures for their utility in helping to lower stroke events: A randomized clinical trial. *Int J Stroke* 2021;16:300–10.

19. Huang YC, Tsai YH, Lee JD, et al. A Novel Neuroimaging Model to Predict Early Neurological Deterioration After Acute Ischemic Stroke. *Curr Neurovasc Res* 2018;15:129–37.

20. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016;388:2532–61.

21. Siegler JE, Martin-Schild S. Early Neurological Deterioration (END) after stroke: the END depends on the definition. *Int J Stroke* 2011;6:211–2.

22. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736–47.

23. van Rooij WJ, Sprengers ME, de Gast AN, et al. 3D rotational angiography: the new gold standard in the detection of additional intracranial aneurysms. *AJNR Am J Neuroradiol* 2008;29:976–9.
Figure 1. A schematic diagram of the treatment schedule and study design.

In the intervention group, patients will take aspirin (300mg loading and 100mg/day), clopidogrel (300mg loading and 75mg/day) and high-intensity statins (atorvastatin 40-80mg/day or rosvastatin 20mg/day) within 24h of stroke onset, followed by aspirin or clopidogrel alone from day 22. High-intensity statins includes atorvastatin 40-80mg/day or rosvastatin 20mg/day. In the historical control group, patients will be selected from previous prospective studies if they fulfill the following inclusion criteria: took aspirin or clopidogrel alone and did not receive high-intensity statin treatment.
Table 1. Inclusion and exclusion criteria (Issue date: 01 Sep 2020)

## Inclusion Criteria
- Clinical diagnosis of ischemic stroke with a National Institute of Health Stroke Scale (NIHSS) score of 1–8
- An ischemic lesion on diffusion-weighted imaging located in the striatocapsular territory or brainstem areas, with an axial diameter ≤20mm.
- Branch atheromatous disease, defined by a visible ischemic lesion in three or more axial cuts on DWI in the lenticulostriate territory or infarcts that extend from the basal surface of the pons.
- Ability to participate within 24h of the time of last known free of new ischemic symptoms.
- Head MRI ruling out hemorrhage or other pathologies, such as vascular malformation, tumor, or abscess, that could explain their symptoms or contraindicate therapy.
- Ability to tolerate high intensity medical therapy, including aspirin at a dose of 50–325mg/day, clopidogrel at 300mg loading and 75mg after day 2 and high-intensity statins (either atorvastatin 40-80mg or rosuvastatin 20mg/day).
- Pre-stroke mRS ≤1

## Exclusion Criteria
- Age <18 years.
- At the judgment of the treating physician.
- A candidate for thrombolysis, endarterectomy or endovascular intervention.
- Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to the index event.
- Patients with >50% stenosis of the relevant arteries as determined by magnetic resonance angiography (MRA), including the intra- or extra-cranial internal carotid artery, middle cerebral artery or basilar artery.
- Patients with a high risk of cardioembolic stroke, such as those with atrial fibrillation, acute myocardial infarction, severe heart failure or valvular heart disease.
- Those with other determined stroke etiologies, such as vasculitis, shock, antiphospholipid antibody syndrome etc.
- Gastrointestinal bleeding or major surgery within 3 months prior to the index event.
- History of nontraumatic intracranial hemorrhage.
- Clear indication for anticoagulation during the study period (deep venous thrombosis, pulmonary embolism or hypercoagulable state).
- Qualifying ischemic event induced by angiography or surgery.
- Severe non-cardiovascular comorbidity with a life expectancy <3 months.
- Contraindication to clopidogrel, aspirin, atorvastatin or rosuvastatin
  - Known allergy to clopidogrel, aspirin atorvastatin or rosuvastatin
  - Severe renal (serum creatinine >2 mg/dL) or hepatic insufficiency (INR >1.2; ALT >40 U/L or any
resultant complication, such as variceal bleeding, encephalopathy, or jaundice)

- Hemostatic disorder or systemic bleeding in the past 3 months
- Current thrombocytopenia (platelet count <100 x10⁹/L) or leukopenia (<2 x10⁹/L)
- History of drug-induced hematologic or hepatic abnormalities

- Anticipated requirement for long-term (>7 day) non-study antiplatelet drugs (e.g., dipyridamole, ticagrelor, ticlopidine), or NSAIDs.
- Not willing or able to discontinue prohibited concomitant medications.
- Women of childbearing age not practicing reliable contraception who do not have a documented negative pregnancy test.
- Other neurological conditions that would complicate assessment of outcomes during follow-up.
- Ongoing treatment in another study of an investigational therapy, or treatment in such a study within the last 7 days.
Figure 1/ A schematic diagram of the treatment schedule and study design
199x109mm (600 x 600 DPI)
Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

**Instructions to authors**

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

| Reporting Item | Number |
|----------------|--------|
| Administrative information | |
| Title | #1 | Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym | 1 |

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
Trial registration  #2a  Trial identifier and registry name. If not yet registered, name of intended registry 3

Trial registration:  #2b  All items from the World Health Organization Trial data set  Registration Data Set 3

Protocol version  #3  Date and version identifier 14

Funding  #4  Sources and types of financial, material, and other support 10

Roles and responsibilities:  
contributorship  #5a  Names, affiliations, and roles of protocol contributors 10

Roles and responsibilities:  
sponsor contact information  #5b  Name and contact information for the trial sponsor 1

Roles and responsibilities:  
sponsor and funder  
role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities 10

Roles and responsibilities:  
committees  #5d  Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and
other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

**Introduction**

Background and rationale

Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention

Background and rationale: choice of comparators

Explanation for choice of comparators

Objectives

Specific objectives or hypotheses

Trial design

Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)

**Methods:**

Participants, interventions, and outcomes

Study setting

Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria  #10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)

Interventions:  #11a Interventions for each group with sufficient detail to allow description replication, including how and when they will be administered

Interventions:  #11b Criteria for discontinuing or modifying allocated modifications interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)

Interventions:  #11c Strategies to improve adherence to intervention protocols, adherance and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)

Interventions:  #11d Relevant concomitant care and interventions that are permitted or prohibited during the trial concomitant care

Outcomes  #12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline  #13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

Sample size  #14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations

Recruitment  #15 Strategies for achieving adequate participant enrolment to reach target sample size

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation  #16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

Allocation concealment mechanism  #16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque,
sealed envelopes), describing any steps to conceal the
sequence until interventions are assigned

Allocation:  #16c Who will generate the allocation sequence, who will enrol
implementation participants, and who will assign participants to

Blinding (masking)  #17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how

Blinding (masking): #17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

Methods: Data

collection,
management, and
analysis

Data collection plan  #18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
Data collection plan: #18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

Data management #19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistics: outcomes #20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

Statistics: additional analyses #20b Methods for any additional analyses (eg, subgroup and adjusted analyses)

Statistics: analysis population and missing data #20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring

Data monitoring: #21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further
details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed.

Data monitoring: #21b Description of any interim analyses and stopping interim analysis guidelines, including who will have access to these interim results and make the final decision to terminate the trial.

Harms #22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.

Auditing #23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor.

Ethics and dissemination

Research ethics approval #24 Plans for seeking research ethics committee / institutional review board (REC / IRB) approval.

Protocol amendments #25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators).
Consent or assent: #26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)

Consent or assent: #26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable

Confidentiality #27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial

Declaration of interests #28 Financial and other competing interests for principal investigators for the overall trial and each study site

Data access #29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators

Ancillary and post trial care #30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation

Dissemination policy: #31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
Dissemination policy: **#31b** Authorship eligibility guidelines and any intended use of authorship professional writers

Dissemination policy: **#31c** Plans, if any, for granting public access to the full reproducible research protocol, participant-level dataset, and statistical code

**Appendices**

Informed consent **#32** Model consent form and other related documentation given to participants and authorised surrogates

Biological specimens **#33** Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 08. June 2021 using [https://www.goodreports.org/](https://www.goodreports.org/), a tool made by the EQUATOR Network in collaboration with Penelope.ai